End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-14 pm EDT
|
5-day change
|
1st Jan Change
|
11.3
CNY
|
+0.89%
|
|
-5.60%
|
-13.14%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,824
|
5,086
|
5,693
|
7,472
|
5,036
|
11,957
|
Enterprise Value (EV)
1 |
3,788
|
5,373
|
6,543
|
8,667
|
6,729
|
14,053
|
P/E ratio
|
27.3
x
|
22.7
x
|
22.9
x
|
32.5
x
|
274
x
|
-9.64
x
|
Yield
|
0.68%
|
0.24%
|
-
|
0.32%
|
0.09%
|
-
|
Capitalization / Revenue
|
2.31
x
|
2.46
x
|
2.41
x
|
2.52
x
|
2.16
x
|
8.48
x
|
EV / Revenue
|
2.29
x
|
2.59
x
|
2.77
x
|
2.92
x
|
2.88
x
|
9.96
x
|
EV / EBITDA
|
11.7
x
|
15.1
x
|
15.4
x
|
22.8
x
|
40.8
x
|
-35.2
x
|
EV / FCF
|
-259
x
|
-17.8
x
|
-13.8
x
|
-18.4
x
|
-13.5
x
|
24.4
x
|
FCF Yield
|
-0.39%
|
-5.62%
|
-7.22%
|
-5.42%
|
-7.43%
|
4.09%
|
Price to Book
|
1.52
x
|
1.87
x
|
1.99
x
|
2.43
x
|
1.65
x
|
6.47
x
|
Nbr of stocks (in thousands)
|
934,967
|
934,967
|
921,145
|
919,061
|
919,061
|
919,061
|
Reference price
2 |
4.090
|
5.440
|
6.180
|
8.130
|
5.480
|
13.01
|
Announcement Date
|
4/22/19
|
4/28/20
|
4/28/21
|
4/19/22
|
4/21/23
|
4/28/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,653
|
2,071
|
2,364
|
2,968
|
2,336
|
1,410
|
EBITDA
1 |
324.5
|
356.1
|
423.8
|
379.7
|
164.8
|
-399.8
|
EBIT
1 |
280.4
|
304
|
368.8
|
324.1
|
108
|
-474.2
|
Operating Margin
|
16.97%
|
14.68%
|
15.6%
|
10.92%
|
4.62%
|
-33.62%
|
Earnings before Tax (EBT)
1 |
171.4
|
261.2
|
301.6
|
260.4
|
18.12
|
-1,232
|
Net income
1 |
140
|
225.3
|
252.8
|
233.6
|
17.51
|
-1,240
|
Net margin
|
8.47%
|
10.88%
|
10.7%
|
7.87%
|
0.75%
|
-87.93%
|
EPS
2 |
0.1500
|
0.2400
|
0.2700
|
0.2500
|
0.0200
|
-1.350
|
Free Cash Flow
1 |
-14.64
|
-301.9
|
-472.6
|
-469.9
|
-499.9
|
575.4
|
FCF margin
|
-0.89%
|
-14.57%
|
-19.99%
|
-15.83%
|
-21.4%
|
40.79%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0280
|
0.0130
|
-
|
0.0260
|
0.005000
|
-
|
Announcement Date
|
4/22/19
|
4/28/20
|
4/28/21
|
4/19/22
|
4/21/23
|
4/28/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
286
|
850
|
1,195
|
1,692
|
2,096
|
Net Cash position
1 |
35.6
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
0.804
x
|
2.006
x
|
3.148
x
|
10.27
x
|
-5.242
x
|
Free Cash Flow
1 |
-14.6
|
-302
|
-473
|
-470
|
-500
|
575
|
ROE (net income / shareholders' equity)
|
5.33%
|
8.48%
|
9.01%
|
7.81%
|
0.33%
|
-51.4%
|
ROA (Net income/ Total Assets)
|
4.75%
|
4.88%
|
5.41%
|
4.15%
|
1.2%
|
-5.57%
|
Assets
1 |
2,945
|
4,616
|
4,671
|
5,629
|
1,457
|
22,248
|
Book Value Per Share
2 |
2.690
|
2.900
|
3.100
|
3.340
|
3.330
|
2.010
|
Cash Flow per Share
2 |
1.090
|
0.6000
|
0.5200
|
0.5900
|
0.8700
|
0.2600
|
Capex
1 |
235
|
163
|
200
|
308
|
431
|
239
|
Capex / Sales
|
14.21%
|
7.89%
|
8.45%
|
10.38%
|
18.46%
|
16.97%
|
Announcement Date
|
4/22/19
|
4/28/20
|
4/28/21
|
4/19/22
|
4/21/23
|
4/28/24
|
|
1st Jan change
|
Capi.
|
---|
| -13.14% | 1.42B | | -1.26% | 89.46B | | +2.76% | 40.74B | | -9.06% | 33.03B | | +55.32% | 24.68B | | -16.61% | 15.12B | | -9.14% | 12.81B | | -12.11% | 11.79B | | -43.61% | 11.64B | | +7.79% | 8.9B |
Biopharmaceuticals
|